Martina Flammer, M.D., Chief Medical Officer of INSMED Inc ($INSM), sold a combined $3,494,838 worth of company shares on August 6, 2026. The two open-market transactions left her with 60,486 shares. Flammer first sold 18,278 shares at $129.40 apiece, totaling $2,365,173, then sold another 8,895 shares at $127.00 each for $1,129,665. The sales were disclosed in a Form 4 filing dated August 7, 2026.
The August 6 trades extended a pattern. Since the start of 2026, Flammer executed 31 open-market sales of $INSM stock, collecting roughly $15.1 million. The sales occurred across January, February, May, July, and August, with the largest single-day total hitting on the most recent filing date. No open-market purchases or equity grants for Flammer appeared on the $INSM ticker during that period.
Other $INSM insiders also sold heavily. CEO William Lewis completed 52 open-market sales between January 6 and July 9, 2026, totaling about $25.4 million. COO Roger Adsett reported eight sales for roughly $16.0 million through mid-May. Chief People Strategy Officer Nicole Schaeffer Orlov sold five blocks on January 2, 2026, amounting to approximately $15.3 million. CLO Michael Alexander Smith recorded 11 sales totaling roughly $8.8 million from January through June, and CFO Sara Bonstein reported five sales worth about $1.9 million through mid-May. Together, $INSM insiders disclosed more than $80 million in open-market sales during the first seven-plus months of 2026.
Insmed, a biotechnology company valued at roughly $21.4 billion, saw its shares trade at $129.40 in the August 6 transaction. The price was down from levels above $150 reached in early February 2026 but above the $100 to $118 range at which Flammer sold shares in May and July.
In Congress, Representative Josh Gottheimer, Democrat of New Jersey, disclosed a sale of $INSM stock on June 10, 2026, with a midpoint value of $1,001. That disclosure was filed on July 7, 2026, 27 days after the trade. Representative Gilbert Cisneros, Democrat of California, reported four separate sales of $INSM stock between July and October 2025, each with a $1,001 midpoint value.